2 July 2020 

Pfizer and BioNTech have reported positive preliminary results from the ongoing Phase I/II clinical trial of BNT162b1, a potential Covid-19 vaccine. The results showed that the vaccine candidate could be given at a dose that was well tolerated and produced dose dependent immunogenicity.

At a UK parliamentary hearing, a researcher from the University of Oxford has said that the University’s Covid-19 vaccine candidate showed ‘the right sort of immune response’ in clinical trials. The vaccine, which has been licensed to AstraZeneca , is currently in Phase III trials on 8,000 volunteers. P

Sorrento Therapeutics has selected T-VIVA-19 as its targeted protein vaccine against Covid-19, as a result of findings from its preclinical vaccination programme. T-VIVA-19 is a recombinant fusion protein consisting of the spike protein S1-domain and the Fc portion of the human IgG1 antibody (rS1-Fc), which triggered antibodies against the SARS-CoV-2 protein in mice.

China National Biotec Group (CNBG) has completed construction of a new plant in Wuhan for Covid-19 vaccines, reported Reuters. The new facility, which has annual capacity of more than 100 million doses, is said to double CNBG’s capacity to over 200 million doses per year.